載入...
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
Deep remission and prolonged disease-free survival can be achieved with first-line chemoimmunotherapy (CIT), such as combined fludarabine, cyclophosphamide, and rituximab, in the majority of patients with chronic lymphocytic leukemia (CLL). More modest results are reported with less intense regimens...
Na minha lista:
| 發表在: | Blood |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4828075/ https://ncbi.nlm.nih.gov/pubmed/26576865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-08-634816 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|